Spectacle Films Utilising S.T.O.P.® Technology for Slowing Down Myopia Progression in Children
Key facts
- Who runs it
- nthalmic Pty Ltd
- Where
- China and India5 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 210 people, planned
- Started
- 22 Dec 2023
- Expected to end
- Mar 2028
- Type of study
- Interventional, 5 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Single vision spectacle lens
- Single vision spectacle lens + S.T.O.P.® Kit 1
- Single vision spectacle lens + S.T.O.P.® Kit 2
- Single vision spectacle lens + S.T.O.P.® Film
- Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2
- Record updated
- 17 June 2026
Who can take part
- Age
- 6 years to 14 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Be between 6-14 years inclusive at time of enrolment
- Have:; Read the Informed Assent; Been explained the Informed Assent; Indicated an understanding of the Informed Assent; Signed the Informed Assent
- Have their parent / legal guardian:; Read the Informed Consent; Been explained the Informed Consent; Indicated an understanding of the Informed Consent; Signed the Informed Consent
- Along with their parent / legal guardian, be capable of comprehending the nature of the study, and be willing and able to adhere to study requirements
- Along with their parent / legal guardian, agree to maintain the visit and prescribed wearing schedule
- Agree to wear allocated spectacles for a minimum of 5 days per week, at least 6 hours per day for the duration of the study and to inform the investigator if their schedule is interrupted
- Possess wearable and visually functioning spectacles
- Be in good general health, based on the parent's / legal guardian's knowledge
- Have best-corrected high contrast visual acuity based on manifest refraction of 0.10 logMAR (20/25, 6/7.6) or better in each eye
- Meet the following criteria determined by cycloplegic autorefraction at Baseline:; -5.00 D ≤ spherical equivalent ≤ -0.75 D and sphere component ≤ -0.50 DS; -1.50 DC ≤ astigmatic component ≤ 0 DC; |Spherical equivalent anisometropia| ≤ 1.00 D
Who cannot take part
- Participant is currently, or within 30 days prior to this study, has been an active participant in another study
- Current or prior use of ANY form of myopia control, including but not limited to:; Optical devices:; Bifocal or multifocal spectacles of any type; Bifocal or multifocal contact lenses of any type; Orthokeratology of any type; Pharmacological agents:; Atropine with a concentration > 0.01%. Participants who have previously used 0.01% atropine are eligible for this study provided they agree not to use 0.01% atropine for at least 30 days before baseline and at any time during the study; Pirenzepine
- Habitual use of a systemic or topical medication that may alter normal ocular findings / is known to affect a participant's ocular health / physiology either in an adverse or beneficial manner at enrolment and / or during the clinical trial
- Strabismus as determined by cover test at distance (≥ 3 m) or near (40 cm) while wearing distance correction under non-cycloplegic conditions
- Known ocular or systemic disease, such as but not limited to:; Diabetes; Graves' disease; Glaucoma; Uveitis; Scleritis; Auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjogrens syndrome, and systemic lupus erythematosus
- Any ocular, systemic, or neuro-developmental conditions that could influence refractive development, such as but not limited to:; Persistent pupillary membrane; Vitreous haemorrhage; Cataract; Central corneal scarring; Eyelid haemangiomas; Marfan's syndrome; Down's syndrome; Ehler's-Danlos syndrome; Stickler's syndrome; Ocular albinism; Retinopathy of prematurity
- A known allergy to sodium fluorescein, benoxinate, proparacaine, tropicamide, or cyclopentolate
- Participant born earlier than 30 weeks or weighed < 1500 g at birth; A verbal report from the participant's parent / legal guardian is sufficient
- Keratoconus or irregular cornea
- The investigator may, at their discretion, exclude anyone who they believe may not be able to fulfil the clinical trial requirements or it is believed to be in the participant's best interests
Where is this trial?
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
There are two parts to this trial. First, to compare the rate of myopia progression of spectacle films using Spatio Temporal Optic Phase (S.T.O.P.®) technology that provide a dynamic optical cue against single vision spectacle lenses. Second, to compare the rate of myopia progression of spectacle films using S.T.O.P.® technology that provide a dynamic optical cue against spectacle films using S.T.O.P.® technology that provide a static optical cue. A dynamic optical cue is one that changes, and a static optical cue is one that does not change.
The 5 groups in the trial
- Assigned Intervention 1Existing treatment, for comparison
Single vision spectacle lens
Treatment: Single vision spectacle lens
- Assigned Intervention 2Treatment being tested
Single vision spectacle lens + S.T.O.P.® Kit 1
Treatment: Single vision spectacle lens + S.T.O.P.® Kit 1
- Assigned Intervention 3Treatment being tested
Single vision spectacle lens + S.T.O.P.® Kit 2
Treatment: Single vision spectacle lens + S.T.O.P.® Kit 2
- Assigned Intervention 4Existing treatment, for comparison
Static optical signal: single vision spectacle lens + S.T.O.P.® spectacle film
Treatment: Single vision spectacle lens + S.T.O.P.® Film
- Assigned Intervention 5Treatment being tested
Dynamic optical signal: single vision spectacle lens + S.T.O.P.® Kit 1 or 2
Treatment: Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Spectacle Films Utilising S.T.O.P.® Technology for Slowing Down Myopia Progression in Children: A Prospective, Masked, Controlled, Randomised, Clinical Trial.
- Publications
- Record updated
- 17 June 2026